TRCT
ALDR

Tower Research Capital (TRC)’s Alder Biopharmaceuticals ALDR Stock Holding History

Tower Research Capital (TRC)’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-500
Closed -$5K – 4651
2018
Q4 		$5K Buy
500
+405
+426% +$5.18K ﹤0.01% 2978
2018
Q3 		$2K Sell
95
-7,959
-99% -$144K ﹤0.01% 3525
2018
Q2 		$128K Buy
+8,054
New +$122K 0.01% 1287
2018
Q1 		– Sell
-1,958
Closed -$22K – 4174
2017
Q4 		$22K Buy
+1,958
New +$21.9K ﹤0.01% 2005
2017
Q1 		– Sell
-4,227
Closed -$88K – 4334
2016
Q4 		$88K Buy
4,227
+4,218
+46,867% +$110K 0.01% 1046
2016
Q3 		$0 Buy
+9
New +$274 ﹤0.01% 4908
2016
Q2 		– Sell
-2,434
Closed -$60K – 5295
2016
Q1 		$60K Buy
2,434
+2,122
+680% +$49.1K 0.01% 691
2015
Q4 		$10K Buy
312
+135
+76% +$4.57K ﹤0.01% 2187
2015
Q3 		$6K Sell
177
-794
-82% -$33.8K ﹤0.01% 2720
2015
Q2 		$51K Sell
971
-994
-51% -$36.2K ﹤0.01% 1359
2015
Q1 		$57K Buy
1,965
+1,232
+168% +$33.8K 0.01% 1371
2014
Q4 		$21K Buy
+733
New +$13.2K ﹤0.01% 1578
2014
Q3 		– Sell
-6,058
Closed -$122K – 5118
2014
Q2 		$122K Buy
+6,058
New +$85.3K 0.02% 798

Other funds holding ALDR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Tower Research Capital (TRC)'s ALDR Position: Q1 2019 in Review

Tower Research Capital (TRC) sold out of Alder Biopharmaceuticals (ALDR) in Q1 2019, closing a stake of 500 shares — an estimated $5K sold.

Tower Research Capital (TRC) first reported a position in ALDR in Q2 2014 and held it in 13 quarters. The position peaked at $128K in Q2 2018. 123 funds tracked by Wall St. Rank hold ALDR as of Q1 2019.

  • Tower Research Capital (TRC) reported no remaining Alder Biopharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 500 Alder Biopharmaceuticals shares in Q1 2019, an estimated $5K.
  • Tower Research Capital (TRC) first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 13 quarters.
  • Tower Research Capital (TRC)'s Alder Biopharmaceuticals position peaked at $128K in Q2 2018.
  • 123 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2019.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2019, filed 14 May 2019.